ORIGINAL ARTICLE: Correction of Anemia with Epoetin Alfa in Chronic Kidney Disease
16th Nov 2006, 15:30 GMT
Recombinant human erythropoietin is indicated for the correction of anemia in chronic kidney disease, but the optimal target level of hemoglobin is unknown. In this open-label study, epoetin alfa was given to achieve a high (13.5 g per deciliter) or a low (11.3 g per deciliter) target hemoglobin level. The higher target level was associated with an increased risk of adverse events without an improvement in quality of life.
Latest news from New England Journal of Medicine -- Recent Issues:
- EARLY RELEASE: Reducing the Door-to-Balloon Time for Myocardial Infarction with ST-Segment Elevation
- EARLY RELEASE: Strategies for Reducing the Door-to-Balloon Time in Acute Myocardial Infarction
- EARLY RELEASE: Myocardial Infarction and the Open-Artery Hypothesis
- EARLY RELEASE: Coronary Intervention for Persistent Occlusion after Myocardial Infarction
- PERSPECTIVE: Recalibrating Medicare Payments for Inpatient Care
- PERSPECTIVE: Violence and Mental Illness -- How Strong is the Link?
- PERSPECTIVE: Murder or Mercy? Hurricane Katrina and the Need for Disaster Training
- ORIGINAL ARTICLE: Normalization of Hemoglobin Level in Patients with Chronic Kidney Disease and Anemia
- ORIGINAL ARTICLE: Tolvaptan, a Selective Oral Vasopressin V2-Receptor Antagonist, for Hyponatremia
- ORIGINAL ARTICLE: Treatment of Coronary In-Stent Restenosis with a Paclitaxel-Coated Balloon Catheter